-+ 0.00%
-+ 0.00%
-+ 0.00%

Apogee Therapeutics to report 16-week Phase 2 APEX data for zumilokibart in atopic dermatitis on May 27

PUBT·05/26/2026 20:01:34
Listen to the news
Apogee Therapeutics to report 16-week Phase 2 APEX data for zumilokibart in atopic dermatitis on May 27
  • Apogee Therapeutics scheduled release of Part B 16-week results from the Phase 2 APEX trial of zumilokibart in moderate-to-severe atopic dermatitis.
  • Data will be presented on May 27, 2026, followed by an 8:00 a.m. ET conference call and webcast.
  • Zumilokibart is Apogee’s lead biologic program, positioned as a potential best-in-class therapy with less frequent dosing in large inflammation markets.
  • The readout is a key near-term catalyst for the company’s atopic dermatitis strategy, with additional development planned in asthma and eosinophilic esophagitis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apogee Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605261601PRIMZONEFULLFEED9726618) on May 26, 2026, and is solely responsible for the information contained therein.